2007 could be a pivotal year, bringing new technologies and
positive clinical developments for therapeutic cancer
New technologies include DNA and cellular delivery, TLR
receptor agonists, and adjuvants.
Recent News is that five well-funded public companies with
proprietary technology and late-stage trials utilizing
active immunotherapy along with combination therapy to
complement antibody treatment and chemotherapy.
One of the method namely "Dendrion" is to use a selected
cancer?related target protein to stimulate a patient?s own
dendritic cells, which are then reinfused into the patient
to stimulate an immune response.
Dendreon also completed a Phase I evaluation of Neuvenge, an
investigative active cellular immunotherapy for the
treatment of breast, ovarian, and colon cancers.
| Swapna |